...
首页> 外文期刊>Journal of interferon and cytokine research: The official journal of the International Society for Interferon and Cytokine Research >Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.
【24h】

Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.

机译:与可溶性I型干扰素受体IFNAR-2形成人IFN-β复合物可在异种SCID小鼠体内增强IFN的稳定性,药代动力学和抗肿瘤活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Interferon-beta (IFN-beta) is biologically unstable under physiologic conditions in vitro and is cleared rapidly from the bloodstream on administration in vivo. In the present study, we demonstrate that a soluble recombinant form of the type I IFN receptor subunit, sIFNAR-2, can neutralize the bioactivity of type I IFNs at high concentrations and, at lower concentrations, causes an enhancement of IFN-beta-mediated antiviral activity. The in vitro enhancement is due to the specific interaction of IFN-beta with sIFNAR-2, followed by dissociation of IFN-beta from the complex over time in culture. In vivo, the serum half-life of IFN-beta is extended from minutes to hours when administered intravenously in mice as a sIFNAR-2-associated complex. Moreover, the antitumor effect of IFN-beta is increased by between 9-fold and 27-fold when injected as an sIFNAR-2-associated complex, as demonstrated by an increase in the mean survival time of immunodeficient mice challenged with human Burkitt lymphoma cell (Daudi)xenografts (sIFNAR-2-complexed vs. free IFN-beta treatment). These results show that on association with sIFNAR-2, IFN-beta is more stable in vitro and exhibits increased efficacy when administered in vivo. Administration as a complex with sIFNAR-2 may, therefore, provide a method of enhancing the delivery and effectiveness of type I IFNs.
机译:干扰素-β(IFN-beta)在体外生理条件下生物学上不稳定,在体内给药后会迅速从血流中清除。在本研究中,我们证明了可溶性重组体形式的I型IFN受体亚基sIFNAR-2在高浓度下可中和I型IFN的生物活性,在较低浓度下可引起IFN-β介导的增强抗病毒活性。体外增强是由于IFN-β与sIFNAR-2的特异性相互作用,随后随着培养时间的延长,IFN-β从复合物中解离出来。在体内,当以sIFNAR-2相关复合物静脉注射给小鼠时,IFN-β的血清半衰期从数分钟延长至数小时。此外,以sIFNAR-2相关复合物的形式注射时,IFN-β的抗肿瘤作用提高了9倍至27倍,这可以通过用人Burkitt淋巴瘤细胞攻击的免疫缺陷小鼠的平均存活时间增加来证明(Daudi)异种移植物(sIFNAR-2复合物与游离IFN-beta处理)。这些结果表明,在与sIFNAR-2结合时,IFN-β在体外更稳定并且在体内施用时表现出增加的功效。因此,作为与sIFNAR-2的复合物给药可以提供增强I型IFN的递送和有效性的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号